Lynn E. Spitler

Spitler Oncology is a clinical-stage biotechnology company focused on the development of personalized cancer immunotherapies, specifically for the treatment of malignant melanoma. Founded and led by Dr. Lynn E. Spitler, a pioneer in melanoma research, the company has focused on the development of autologous melanoma vaccines and dendritic cell-based therapies. The company's primary efforts have centered on the Northern California Melanoma Center, where clinical trials have evaluated the efficacy of patient-specific vaccines in preventing recurrence in high-risk melanoma patients. Spitler Oncology represents a specialized research and development entity dedicated to advancing immunological approaches to skin cancer treatment.